Clinical role of obinutuzumab in the treatment of naive patients with chronic lymphocytic leukemia

Biologics : Targets & Therapy
Sonia Cerquozzi, Carolyn Owen

Abstract

The introduction of targeted therapy against CD20(+) with the monoclonal antibody rituximab has dramatically improved the survival of B-cell non-Hodgkin lymphoma including chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma. Unfortunately, CLL remains incurable with chemoimmunotherapy, with many patients having refractory or relapsing disease after rituximab-containing therapy. Obinutuzumab (GA101) is a novel humanized Type II anti-CD20 monoclonal antibody that has been investigated and compared to rituximab. Here, we provide an overview of obinutuzumab, including its mechanisms of action, preclinical data, and Phase I to III clinical studies. Preclinical data illustrate obinutuzumab's higher potency compared to rituximab through antibody-dependent cellular cytotoxicity and direct cell death. Recently, the CLL11 study presented a significant benefit from obinutuzumab chemoimmunotherapy and supports its use for treatment-naive unfit CLL patients. Herein, we review that obinutuzumab is both a safe and effective alternative to rituximab.

Citations

Oct 25, 2016·Trends in Biotechnology·Hye In ParkSang Taek Jung
Jan 10, 2018·Frontiers in Immunology·Isabel Corraliza-GorjónLeonor Kremer

❮ Previous
Next ❯

Datasets Mentioned

BETA
ABT-199

Methods Mentioned

BETA
xenograft

Clinical Trials Mentioned

NCT01905943
NCT01685892
NCT02242942

Related Concepts

Related Feeds

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

Antibody-Dependent Cell Cytotoxicity

Antibody-dependent cellular toxicity refers to the lysis of a target cell by a non-sensitized effector cell of the immune system as a result of antibodies binding to the target cell membrane and engaging the Fc receptors on the immune effector cells. Find the latest research on antibody-dependent cellular toxicity here.

Related Papers

Expert Opinion on Biological Therapy
Carolyn Owen, Douglas A Stewart
Expert Review of Hematology
Catherine Rioufol, Gilles Salles
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners
Ashish Kumar Kakkar, Sadasivam Balakrishnan
Expert Opinion on Biological Therapy
Tim IllidgeJamie Honeychurch
© 2022 Meta ULC. All rights reserved